Men's Hair Loss: Causes, Treatments, and What Actually Works

What Causes Hair Loss in Men?

Androgenetic alopecia accounts for more than 95% of hair loss in men, according to the American Academy of Dermatology [1]. The condition is polygenic, meaning multiple genes inherited from both parents contribute to susceptibility. Hair does not simply fall out. Instead, follicles gradually miniaturize under the influence of DHT, a potent androgen converted from testosterone by the enzyme 5-alpha reductase.

DHT binds to androgen receptors in genetically susceptible follicles, shortening the anagen (growth) phase and producing progressively thinner, shorter hairs [2]. Over years, terminal hairs become vellus-like wisps until the follicle produces no visible hair at all. The Norwood-Hamilton scale classifies this progression from mild temporal recession (type II) through complete vertex and frontal loss (type VII).

Not every case of male hair thinning is androgenetic. Telogen effluvium, a diffuse shedding triggered by physiological stress, illness, or nutritional deficiency, can mimic early pattern loss. Alopecia areata, an autoimmune condition causing patchy bald spots, requires a different treatment approach entirely. Thyroid dysfunction, iron deficiency, and certain medications (including some blood pressure drugs and antidepressants) also cause reversible hair loss [3]. A proper diagnosis matters because the treatment plan depends on the mechanism.

How DHT Drives Male Pattern Baldness

DHT is two to three times more potent than testosterone at activating androgen receptors [4]. In scalp tissue, type II 5-alpha reductase converts circulating testosterone into DHT within the dermal papilla cells of hair follicles. Men with androgenetic alopecia have higher concentrations of androgen receptors in frontal and vertex scalp tissue compared to occipital (back of head) regions, which explains the characteristic pattern of loss [2].

This receptor density difference is why hair transplants work. Follicles harvested from the occipital donor area retain their DHT resistance even when relocated to balding zones. The follicle carries its genetic programming with it. A 2019 review in the Journal of the American Academy of Dermatology confirmed that transplanted hairs maintain donor-area characteristics for decades after surgery [5].

The Hamilton study from 1942 first demonstrated this hormonal link: castrated men who lacked circulating testosterone did not develop baldness, and administering testosterone to castrated men with a genetic predisposition triggered hair loss [6]. This finding became the foundation for every anti-androgen hair loss therapy developed since.

Finasteride: The First-Line Oral Treatment

Finasteride 1 mg (brand name Propecia) remains the most effective single oral treatment for male androgenetic alopecia. It works by inhibiting type II 5-alpha reductase, reducing scalp DHT levels by approximately 64% and serum DHT by about 70% [7].

The key phase III trial enrolled 1,553 men aged 18 to 41 with mild to moderate vertex hair loss. At 2 years, 66% of men on finasteride showed hair regrowth based on hair count, compared to 7% on placebo. The mean increase was 138 hairs in a 5.1 cm² target area [7]. A 5-year extension study showed sustained benefit, with 48% of men on finasteride rated as improved by an expert panel versus 25% of placebo patients [8].

Sexual side effects are the primary concern. In controlled trials, erectile dysfunction occurred in 1.3%, decreased libido in 1.8%, and ejaculatory disorders in 1.2% of men on finasteride versus 0.7%, 1.3%, and 0.7% on placebo, respectively [7]. These differences are statistically small. Symptoms resolved in most men who discontinued the drug and also in 58% of men who continued treatment. The concept of "post-finasteride syndrome," a persistent constellation of sexual and neurological symptoms after stopping finasteride, has been described in case reports, but no controlled prospective study has established a causal mechanism or defined its true prevalence [9].

Dr. Antonella Tosti, Professor of Dermatology at the University of Miami Miller School of Medicine, has stated: "Finasteride is the most important treatment we have for male pattern hair loss. The risk-benefit ratio strongly favors treatment, especially when started before significant miniaturization has occurred."

Minoxidil: Topical Regrowth Without a Prescription

Minoxidil 5% (brand name Rogaine) is the other FDA-approved treatment for male pattern hair loss and is available over the counter [10]. Originally developed as an oral antihypertensive, its hair growth properties were discovered as a side effect. The exact mechanism is not fully understood, but minoxidil acts as a potassium channel opener that prolongs anagen phase and increases follicular blood flow.

A 48-week randomized controlled trial (N=393) found that 5% topical minoxidil produced 45% more hair regrowth than 2% minoxidil at the vertex [10]. The 5% formulation is the standard for men. Foam preparations tend to cause less scalp irritation than solution formulations containing propylene glycol. Application must be consistent. Stopping minoxidil leads to loss of all treatment-related gains within 3 to 6 months.

Oral low-dose minoxidil (0.25 mg to 5 mg daily) has gained traction as an off-label alternative. A retrospective study of 1,404 patients published in the Journal of the American Academy of Dermatology found that oral minoxidil at doses of 1.25 mg to 2.5 mg daily produced clinically meaningful improvement in 60% to 65% of men with androgenetic alopecia [11]. Hypertrichosis (unwanted body hair growth) occurred in 15.1% of patients, and peripheral edema in 1.7%. Oral minoxidil should be prescribed with caution in patients with cardiovascular disease.

Combination Therapy: Why Two Drugs Beat One

Using finasteride and minoxidil together produces superior results compared to either agent alone. A 12-month randomized trial (N=450) directly compared finasteride 1 mg, minoxidil 5%, and the combination. The combination group showed significantly greater hair count increases than either monotherapy group [12].

The rationale is straightforward. Finasteride blocks the hormonal driver of follicle miniaturization. Minoxidil stimulates growth through a separate, non-hormonal pathway. The two mechanisms are complementary rather than redundant.

A practical approach for most men with Norwood III or higher: start finasteride 1 mg daily plus topical minoxidil 5% twice daily, assess at 6 and 12 months with standardized photographs, and adjust based on response. Men who cannot tolerate oral finasteride may consider topical finasteride 0.25% solution, which delivers lower systemic exposure while still reducing scalp DHT. A phase II study showed topical finasteride 0.25% reduced scalp DHT by 47% compared to 62% with oral finasteride 1 mg, with no significant difference in serum testosterone or DHT levels between topical and placebo groups [13].

Dutasteride: A More Potent Alternative

Dutasteride inhibits both type I and type II 5-alpha reductase, reducing serum DHT by over 90% compared to finasteride's 70% [14]. While FDA-approved for benign prostatic hyperplasia (BPH) at 0.5 mg daily, dutasteride is used off-label for hair loss in many countries. South Korea and Japan have approved it for androgenetic alopecia.

A phase III randomized trial (N=917) compared dutasteride 0.5 mg to finasteride 1 mg and placebo over 24 weeks. Dutasteride produced significantly greater increases in hair count (12.2 hairs/cm²) compared to finasteride (4.6 hairs/cm²) at the vertex target area [14]. The 2019 International Society of Hair Restoration Surgery practice census reported growing adoption of dutasteride among hair loss specialists globally.

The more potent DHT suppression comes with a tradeoff. Sexual side effects in the dutasteride BPH trials occurred at slightly higher rates: erectile dysfunction in 4.7% versus 3.4% placebo, decreased libido in 3.0% versus 1.7% placebo [15]. Dutasteride also has a substantially longer half-life (5 weeks versus 6 to 8 hours for finasteride), meaning side effects take longer to resolve after discontinuation. For these reasons, most guidelines recommend finasteride as first-line, reserving dutasteride for finasteride non-responders.

Emerging Therapies and Procedures

Several newer approaches show promise for men who do not respond adequately to finasteride and minoxidil.

Platelet-rich plasma (PRP). PRP involves drawing the patient's blood, concentrating platelets, and injecting the concentrate into the scalp. A meta-analysis of 12 randomized controlled trials (total N=524) published in Dermatologic Surgery found that PRP increased hair density by a mean of 33.6 hairs/cm² compared to placebo injections [16]. Protocols vary widely across clinics, and no standardized preparation method exists. Typical treatment requires 3 to 4 sessions spaced 4 to 6 weeks apart, with maintenance injections every 6 to 12 months.

Low-level laser therapy (LLLT). FDA-cleared laser devices (combs, caps, helmets) emit red light at 650 to 670 nm wavelengths. A 26-week randomized sham-controlled trial (N=110) showed a significant increase in hair density in the LLLT group compared to sham [17]. Effect sizes are modest compared to pharmacotherapy, and LLLT works best as an adjunct rather than standalone treatment.

Hair transplant surgery. Follicular unit transplantation (FUT) and follicular unit extraction (FUE) are the two primary surgical techniques. FUE removes individual follicular units without a linear scar. Both techniques produce permanent results in the transplanted area because donor follicles retain their genetic resistance to DHT. According to the International Society of Hair Restoration Surgery, the average hair transplant involves 2,000 to 3,000 grafts per session [18]. Patients should stabilize hair loss with medical therapy before surgery and continue medication afterward to prevent further native hair loss around the transplanted follicles.

When to See a Doctor About Hair Loss

Early intervention produces the best outcomes. Once a follicle has been miniaturized for years and the dermal papilla has atrophied, no medication can reverse it. Only surgery can restore hair in areas of complete baldness. The clinical window for medical treatment is widest when hair is thinning, not gone.

See a dermatologist or hair loss specialist if you notice progressive thinning at the temples or crown, increased hair shedding lasting more than 2 to 3 months, or patchy bald spots that could suggest alopecia areata. A basic workup should include thyroid function tests (TSH, free T4), complete blood count, ferritin, and possibly serum testosterone and DHEA-S to rule out secondary causes [3].

The American Academy of Dermatology recommends that men with androgenetic alopecia be counseled on both FDA-approved treatments and realistic expectations [1]. Hair regrowth is not guaranteed, and the primary goal of treatment for many men is stabilization rather than full restoration. Photographs taken under consistent lighting at baseline, 6 months, and 12 months provide the most reliable measure of treatment response.

According to the 2023 guidelines from the British Association of Dermatologists: "Treatment should be initiated early in the disease course, as the response to pharmacotherapy diminishes as hair loss becomes more advanced" [19].

Lifestyle Factors and Hair Health

No supplement or diet replaces finasteride or minoxidil for androgenetic alopecia. Biotin deficiency can cause hair thinning, but true biotin deficiency is rare in developed countries, and supplementation in biotin-sufficient individuals has no demonstrated benefit for hair growth [20]. The supplement industry generates significant revenue from hair growth claims that lack rigorous evidence.

Iron deficiency (ferritin <30 ng/mL) is associated with telogen effluvium, a diffuse shedding pattern distinct from androgenetic alopecia. Correcting iron stores can resolve this type of hair loss. Zinc and vitamin D deficiencies have also been linked to hair shedding in observational studies, though supplementation trials remain limited [3].

Stress is a real contributor. Acute physiological stress (surgery, severe illness, crash dieting) can trigger telogen effluvium 2 to 4 months after the event. Chronic psychological stress may worsen androgenetic alopecia through cortisol-mediated effects on hair follicle cycling, though the evidence is largely preclinical [21]. Sleep deprivation, smoking, and excessive alcohol use are also associated with accelerated hair loss in epidemiological studies.

Resistance training and exercise do not cause hair loss. The persistent myth that weight lifting raises testosterone and worsens baldness is not supported by evidence. Exercise-induced testosterone elevations are transient and minor, insufficient to meaningfully alter scalp DHT levels.

What to Expect from Treatment: Realistic Timelines

Finasteride and minoxidil both require patience. Most men see initial results between 3 and 6 months, with maximum benefit at 12 to 24 months. Some men experience an initial "shedding phase" in the first 1 to 3 months of minoxidil use, where weaker hairs are pushed out by new growth. This is a normal sign the treatment is working.

A 5-year follow-up of finasteride users found that hair counts remained above baseline in 90% of men who continued treatment [8]. Among those switched to placebo after 1 year, hair counts returned to pretreatment levels within 12 months. Both finasteride and minoxidil are indefinite therapies. Stopping them means losing all treatment-related benefit.

For men who start finasteride 1 mg daily before Norwood type IV, the expected outcome after 12 months is stabilization (no further loss) in approximately 85% to 90% and visible regrowth in 50% to 65%, based on pooled trial data [7][8].